CD274 and neoplasm: Given that anti–PD-1/PD-L1 therapies are frequently combined with other drug classes, including other immunotherapies, targeted therapies, and cytotoxic chemotherapies, it also remains to be determined whether multidrug regimens may overcome the prognostic effect of tumor burden.